Pharmax opens generics plant in Dubai

Wockhardt Dubai
UAE-based Pharmax has begun production at a new facility in Dubai shortly after India's Wockhardt recently opened this plant there. (Wockhardt)

After a three-year project, Pharmax Pharmaceuticals is now producing generic drugs in a small but new plant in Dubai.

The UAE-based drugmaker has opened the AED125 million ($34 million) facility located in Dubai Science Park, reported the Arabian Business, citing a company statement. The facility, which has an annual capacity of more than 200 million tablet and capsule dosage forms, has 40 employees and intends to add another 15 in the next few months.

The project is a joint venture of UAE drug distributor Al Ittihad Drug Store and Cooper Pharma and Bottu Pharmaceuticals, both based in Morocco, according to Arabian Business. The company will make a wide variety of drugs including medications for cardiovascular diseases, psychiatric and neurological disorders, gastroenterological diseases, and diabetes.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Wockhardt builds $40M plant in Dubai to produce ‘superbug’ fighters

The opening of the Pharmax plant comes just weeks after India’s Wockhardt announced it had inaugurated a 10,000-square-meter (107,639-square-foot) facility in the Jebel Ali Free Zone in Dubai to make antibiotics. The manufacturing and R&D project includes production of aseptic dry powder and filling, as well as warehousing, product testing and product stability.

It is being built to produce the novel antibiotics that Wockhardt is developing for sale globally. The company said it has five novel drugs that the FDA has granted Qualified Infectious Disease Program (QIDP) status.

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.